News Focus
News Focus
icon url

Investor2014

10/17/25 9:51 PM

#503513 RE: kevindenver #503511

Here:

With newly available preliminary efficacy results of surrogate biomarkers, we consider initiating discussions with regulatory agencies for the Accelerated Approval Pathway for ANAVEX2-73. In parallel, we plan to proceed with the initiation of our confirmatory Alzheimer’s disease study.


— Q2 2023 Earnings Call Transcript, Anavex

https://mlq.ai/stocks/0HFR.L/earnings-call-transcript/Q2-2023 or any other ref. to same.

Facts are important to note also as a biotech investor and indeed to avoid suspicions that people deliberately lie to pee on your sugar sandwich dreams.